- Home
- NHI vs VKTX Comparison
NHI vs VKTX Comparison
Compare NHI & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NHI
- VKTX
- Stock Information
- Founded
- NHI 1991
- VKTX 2012
- Country
- NHI United States
- VKTX United States
- Employees
- NHI N/A
- VKTX N/A
- Industry
- NHI Real Estate Investment Trusts
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- NHI Real Estate
- VKTX Health Care
- Exchange
- NHI Nasdaq
- VKTX Nasdaq
- Market Cap
- NHI 3.3B
- VKTX 2.8B
- IPO Year
- NHI 1991
- VKTX 2015
- Fundamental
- Price
- NHI $70.63
- VKTX $27.84
- Analyst Decision
- NHI Buy
- VKTX Buy
- Analyst Count
- NHI 4
- VKTX 12
- Target Price
- NHI $85.75
- VKTX $84.00
- AVG Volume (30 Days)
- NHI 312.6K
- VKTX 3.8M
- Earning Date
- NHI 08-05-2025
- VKTX 07-23-2025
- Dividend Yield
- NHI 5.12%
- VKTX N/A
- EPS Growth
- NHI 3.74
- VKTX N/A
- EPS
- NHI 3.16
- VKTX N/A
- Revenue
- NHI $343,615,000.00
- VKTX N/A
- Revenue This Year
- NHI $6.97
- VKTX N/A
- Revenue Next Year
- NHI $10.70
- VKTX N/A
- P/E Ratio
- NHI $22.27
- VKTX N/A
- Revenue Growth
- NHI 7.49
- VKTX N/A
- 52 Week Low
- NHI $65.13
- VKTX $18.92
- 52 Week High
- NHI $86.13
- VKTX $81.73
- Technical
- Relative Strength Index (RSI)
- NHI 44.05
- VKTX 53.89
- Support Level
- NHI $69.22
- VKTX $25.80
- Resistance Level
- NHI $70.80
- VKTX $28.80
- Average True Range (ATR)
- NHI 1.30
- VKTX 1.64
- MACD
- NHI 0.01
- VKTX 0.09
- Stochastic Oscillator
- NHI 49.06
- VKTX 79.97
About NHI National Health Investors Inc.
National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments, i.e., Real Estate Investments and Senior Housing Operating Portfolio (SHOP). The Real Estate Investments segment, which generates maximum revenue, consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived in the form of rental income, mortgage and other notes receivable interest income, and resident fees and services.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.